{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.5.7.19, 9.6.1.2, 9.6.3, 9.6.4.2, and 17.1. Additional text is marked in red, underlined, and', 'bolded; deleted text is marked as strikethrough text.', '2 SYNOPSIS', 'Objectives:', 'Secondary Objectives (analyzed hierarchically)', '4.', 'Evaluate the effect of teprotumumab versus placebo on the diplopia responder rate', '(i.e., the percentage of subjects with baseline diplopia > 0 in study eye who have a', 'reduction of 1 grade with no corresponding deterioration 1 grade worsening in', 'the fellow eye) at Week 24.', '5.4.', 'Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to', \"Week 24 in the Graves' Ophthalmopathy Quality of Life (GO-QoL) questionnaire overall\", 'score.', 'Study Design:', 'At the end of the double-masked Treatment Period (Week 24), subjects who are proptosis', 'non-responders (study eye has < 2 mm decrease in proptosis) will be eligible to enter an open-', 'label extension study (HZNP-TEP-302) in which subjects may receive up to 8 infusions of', 'teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) in an', 'open-label fashion.', 'Subjects who complete the Week 72 Visit will be contacted 6 and 12 months later via phone', 'or email by research staff to enquire if any treatment for TED has been received since last', 'study contact. If yes, subject will be questioned regarding type of treatment and', 'outcome/response.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 6 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Double-Masked Treatment Period', 'Follow-Up', 'Screen', 'Baseline', 'Teprotumumab or Placebo 1,2', 'Follow-Up Period', 'Contact5', '48 Weeks 3,4', '24 Weeks', '48 Weeks', 'Clinic Visits', '<', 'Clinic Visits', '>', '*', '*', '*', '*', '*', '2 6', 'Day 6', 'W1', 'W36', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W24', 'W28', 'W36', 'W48', 'W60', 'W72', 'W96', 'W120', 'weeks', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M15', 'M18', 'M24', 'M30', 'predose', 'Randomization', 'Study Week/Month', '>', 'n=38/group 1', '*', 'Infusion of study drug.', '1.', 'Subjects will be randomized in a 1:1 ratio (stratified by tobacco use status) to receive:', 'a. Teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions); or', 'b. Placebo (placebo q3W for all 8 infusions).', '2. Visit windows are 1 day for Weeks 1 and 4, 3 days for Weeks 3, 6, 9, 12, 15, 18, and 21, and 7 days for Week 24.', '3. Subjects who are proptosis responders or non-responders who do not elect to participate in the open-label extension study will enter a 48-week', 'Follow-Up Period. Subjects who are responders at Week 24 but relapse during the Follow-Up Period may enter the open-label study and receive', 'up to-8 infusions if they meet specified criteria.', '4.', 'Visit windows of I 7 days.', '5. Subjects who complete the Week 72 Visit will be contacted via phone or email by research staff to enquire if any treatment for TED has', 'been received since last study contact.', '65. Subjects will be contacted by phone/email the day following the first and second infusions for safety and tolerability assessments; phone/email', 'contacts will also occur the day after any clinic visit where a subject experiences an infusion-related adverse event.', '76. Subjects who are proptosis non-responders at Week 24 of the double-masked Treatment Period will be offered the option to enter an open-label', 'extension study and receive up to 8 additional infusions of teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg for the remaining', '7 infusions all subsequent doses).', 'Inclusion Criteria:', '10.', 'Women of childbearing potential (including those with an onset of menopause <2 years', 'prior to Screening, non-therapy-induced amenorrhea for <12 months prior to Screening, or', 'not surgically sterile [absence of ovaries and/or uterus]) must have a negative serum', 'pregnancy test at Screening and negative urine pregnancy tests at all protocol-specified', 'timepoints (i.e., prior to each dose and through Week 48 of the Follow-Up Period); subjects', 'who are sexually active with a non-vasectomized male partner must agree to use', '2 reliable forms of contraception during the trial, one of which is recommended to be', 'hormonal, such as an oral contraceptive. Hormonal contraception must be started at least', 'one full cycle prior to Baseline and continue for 180 days after the last dose of study drug.', 'Highly effective contraceptive methods (with a failure rate less than 1% per year), when', 'used consistently and correctly, includes implants, injectables, combined oral', 'contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized', 'partner.', '11. Male subjects must be surgically sterile or, if sexually active with a female partner of', 'childbearing potential, must agree to use a barrier contraceptive method from Screening', 'through 180 days after the last dose of study drug.', 'Dose Regimen/Route of Administration:', 'The infusion rate may be reduced and the dose may be interrupted or held based on tolerability', '(see Section 9.4.6.3.2 for details). The first and second infusions will be administered over', 'approximately 90 minutes (but not less than 80 minutes). Subsequent infusions will be', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 7 of 117']\n\n###\n\n", "completion": "END"}